HPM Web Site

  • HPM Web Site

Get Updates via E-mail

  • Enter your email address to automatically receive new posts to the FDA Law Blog via e-mail.

    Delivered by FeedBurner

 Subscribe in a reader

Disclaimer

  • FDA Law Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of FDA Law Blog does not create an attorney-client relationship. FDA Law Blog is the blog of Hyman, Phelps & McNamara, P.C. (“HPM”) and it is intended primarily for other attorneys and regulatory professionals. No part of FDA Law Blog --whether information, commentary, or other-- may be attributed to HPM's clients. Readers should be aware that HPM represents many companies in the food, drug, medical device, and health care industries, and therefore FDA Law Blog may occasionally report on news that relates to HPM clients. FDA Law Blog will always strive to be unbiased in its reporting. All information on FDA Law Blog should be double-checked for its accuracy and current applicability.

    Copyright 2008 Hyman, Phelps & McNamara, P.C.

« Ignoring the NAD Can Be Costly | Main | What Does “May Contain Peanuts” Mean, and When is it False or Potentially Misleading? »

August 15, 2008

A Noteworthy Event for the Drug and Device Industries

Robert A. Dormer of Hyman, Phelps & McNamara, P.C. will be speaking at American Conference Institute’s FDA Boot Camp conference, September 22-23, 2008 at the Sheraton Boston Hotel in Boston, MA. Click here for a copy of the agenda.

At the event, preeminent members of the nation’s Food and Drug bar will

drill products liability and IP/patent lawyers in the basics of current FDA law and regulation — including the nuances of the FDA Amendments Act. They will help you:

  • MASTER the basics of the application and approval processes for drugs, biologics, and devices
  • DEVELOP a practical working knowledge of clinical trials for drugs and biologics and the clearance process for devices
  • APPRECIATE the regulatory balance between brand name and generic products
  • UNDERSTAND the complexities of the patent and IP landscape, including Hatch-Waxman, Orange Book, 180-day exclusivity, 30-month stay, Paragraph IV, NDA, ANDA and 505(b)(2)
  • RECOGNIZE the role of labeling in the drug/biological product approval process
  • SEE the importance of cGMPs to the post-approval regulatory process
  • NAVIGATE the protocols of adverse events monitoring, pharmacovigilance, and Risk Evaluation and Minimization Strategies (REMS)
  • LEARN how devices are classified, monitored, and regulated
  • EXPLORE FDA’s expectations and guidance for recalls

Additional details and registration information are available at the American Conference Institute’s website or by calling 888-224-2480. If you register by or before August 29th, you can lock in the lowest rate.

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d8341d150c53ef00e553e7641e8833

Listed below are links to weblogs that reference A Noteworthy Event for the Drug and Device Industries:

Comments

Verify your Comment

Previewing your Comment

This is only a preview. Your comment has not yet been posted.

Working...
Your comment could not be posted. Error type:
Your comment has been saved. Comments are moderated and will not appear until approved by the author. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.

Working...

Post a comment

Comments are moderated, and will not appear until the author has approved them.